Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sotrovimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/hospitalization 25% Improvement Relative Risk Sotrovimab for COVID-19  Bell et al.  EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 546,317 patients in the USA (May 2021 - April 2022) Lower death/hosp. with sotrovimab (p=0.004) c19early.org Bell et al., Value in Health, June 2023 Favors sotrovimab Favors control

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)

Bell et al., Value in Health, doi:10.1016/j.jval.2023.03.176
Jun 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Sotrovimab for COVID-19
40th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.0016 from 22 studies, recognized in 36 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
N3C IPTW retrospective 4,992 COVID-19 patients in the USA treated with sotrovimab and 541,325 controls, showing lower combined hospitalization or mortality.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene c19early.org, c19early.org (B), vitamin D c19early.org (C), etc.) — either because the physician recommending sotrovimab also recommended them, or because the patient seeking out sotrovimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate the efficacy of treatments.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 Liu, Sheward, VanBlargan, BA.4, BA.5 Haars, XBB.1.9.3, XBB.1.5.24, XBB.2.9, CH.1.1 Pochtovyi, and no efficacy for BA.2 Zhou, ХВВ.1.9.1, XBB.1.16, BQ.1.1.45, and CL.1 Pochtovyi. US EUA has been revoked.
risk of death/hospitalization, 25.1% lower, RR 0.75, p = 0.004, NNT 107, odds ratio converted to relative risk, propensity score weighting, day 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bell et al., 12 Jun 2023, retrospective, USA, peer-reviewed, 11 authors, study period 26 May, 2021 - 30 April, 2022.
This PaperSotrovimabAll
THE EFFECTS OF OBESITY AND METABOLIC SYNDROME ON KIDNEY TRANSPLANT OUTCOMES IN YOUNG PATIENTS: A RETROSPECTIVE STUDY
D ' Souza
propensity score matched and adjusted linear regression. Results: Of 135,729 patients meeting our study criteria, 12,848 remained after 1:1 propensity score matching. Cardiovascular outcomes did not differ significantly between those on an SGLT2i and metformin (hazard ratio: 1.025 [95% CI: 0.901, 1.166]). Among those with baseline and 12-month A1c values available (n = 5,472), SGLT2i use was associated with a smaller absolute decrease in A1c by 0.25% (0.19% -0.32%). Conclusions: In a real-world EHR dataset, patients initiated on an SGLT2i had similar risk of cardiovascular events to those initiated on metformin, but experienced a smaller 12-month reduction in A1c.
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit